tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Oncopeptides’ Pepaxti Gains Inclusion in European Multiple Myeloma Treatment Guidelines

Story Highlights
Oncopeptides’ Pepaxti Gains Inclusion in European Multiple Myeloma Treatment Guidelines

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Oncopeptides AB ( (SE:ONCO) ) has provided an update.

Oncopeptides AB announced that its drug Pepaxti has been included in the European guidelines for treating relapsed, refractory multiple myeloma, marking a significant recognition of its clinical value. This inclusion is expected to enhance Pepaxti’s awareness and usage across Europe, providing a crucial treatment option for patients with limited alternatives, and reflects the growing trust in its efficacy.

More about Oncopeptides AB

Oncopeptides is a Swedish biotech company focusing on research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company utilizes its proprietary Peptide Drug Conjugate platform to develop compounds that selectively deliver cytotoxic agents into cancer cells. Oncopeptides is commercializing its flagship drug in Europe and has partnership agreements in South Korea, the Middle East, and Africa. Founded in 2000, the company operates in several European countries and is listed on Nasdaq Stockholm.

Average Trading Volume: 637,007

Current Market Cap: SEK362.5M

For detailed information about ONCO stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1